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Abstract 
Modern oncology aims at patient-specific therapy approaches, which triggered the development of 
biomedical imaging techniques to synergistically address tumor biology at the cellular and molecular 
level. PET/MR is a new hybrid modality that allows acquisition of high-resolution anatomic images 
and quantification of functional and metabolic information at the same time. Key steps of the 
Warburg effect-one of the hallmarks of tumors-can be measured non-invasively with this emerging 
technique. The aim of this study was to quantify and compare simultaneously imaged augmented 
glucose uptake and LDH activity in a subcutaneous breast cancer model in rats (MAT-B-III) and to 
study the effect of varying tumor cellularity on image-derived metabolic information.  
Methods: For this purpose, we established and validated a multimodal imaging workflow for a 
clinical PET/MR system including proton magnetic resonance (MR) imaging to acquire accurate 
morphologic information and diffusion-weighted imaging (DWI) to address tumor cellularity. 
Metabolic data were measured with dynamic [18F]FDG-PET and hyperpolarized (HP) 13C-pyruvate 
MR spectroscopic imaging (MRSI). We applied our workflow in a longitudinal study and analyzed the 
effect of growth dependent variations of cellular density on glycolytic parameters.  
Results: Tumors of similar cellularity with similar apparent diffusion coefficients (ADC) showed a 
significant positive correlation of FDG uptake and pyruvate-to-lactate exchange. Longitudinal DWI 
data indicated a decreasing tumor cellularity with tumor growth, while ADCs exhibited a significant 
inverse correlation with PET standard uptake values (SUV). Similar but not significant trends were 
observed with HP-13C-MRSI, but we found that partial volume effects and point spread function 
artifacts are major confounders for the quantification of 13C-data when the spatial resolution is 
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limited and major blood vessels are close to the tumor. Nevertheless, analysis of longitudinal data 
with varying tumor cellularity further detected a positive correlation between quantitative PET and 
13C-data.  
Conclusions: Our workflow allows the quantification of simultaneously acquired PET, MRSI and 
DWI data in rodents on a clinical PET/MR scanner. The correlations and findings suggest that a 
major portion of consumed glucose is metabolized by aerobic glycolysis in the investigated tumor 
model. Furthermore, we conclude that variations in cell density affect PET and 13C-data in a similar 
manner and correlations of longitudinal metabolic data appear to reflect both biochemical processes 
and tumor cellularity. 
Key words: PET/MR, [18F]FDG-PET, hyperpolarized 13C-MRSI, DNP, diffusion-weighted imaging, multimodal 
imaging, NMR, spectroscopy 
Introduction 
The new paradigm in oncology is to tailor 
therapies for patient-specific phenotypes, which 
triggered the invention of powerful hybrid imaging 
modalities that address tumor biology in greater 
depth. PET/CT (positron emission tomography/ 
computed tomography) has become commercially 
available at the beginning of this century and is 
currently the work-horse in clinical routine for 
diagnosis, staging, monitoring of response to 
treatment and outcome prediction of cancer patients. 
During the last decade, PET/MR has been introduced 
as a promising new hybrid modality that is 
potentially superior to PET/CT [1]. This is mainly 
because MR has an excellent soft-tissue contrast that is 
not available with CT and delivers accurate 
high-resolution anatomical images close to CT 
resolution and without additional radiation exposure. 
Furthermore, it allows quantitative functional 
imaging (fMRI), diffusion-weighted imaging (DWI) 
and metabolic imaging with hyperpolarized 
13C-labelled metabolites [2-5]. 
One of the main hallmarks of tumors that can be 
addressed non-invasively with metabolic imaging is 
the Warburg effect [6, 7]. Solid tumors consume 
abnormally high levels of glucose and catabolize it 
through inefficient glycolysis, which is an ubiquitous 
feature of tumors that malignant cells benefit from, 
e.g., through fast energy production [8]. Pyruvate is 
the final product of glycolysis and the nexus of the 
entire metabolic network. Even under normoxic 
conditions, it is mainly reduced to lactate by 
fermentation rather than oxidized [9-13]. 
2-deoxy-2-[18]fluoro-D-glucose (FDG) is an 
established clinical PET tracer that can be used for 
qualitative and quantitative characterization of tissues 
with high energy demands [14, 15]. Like glucose, it is 
taken up from the blood stream by glucose 
transporters and phosphorylated by hexokinase once 
it is internalized. FDG is finally trapped and 
accumulates in the cytosol because it is not amenable 
to the subsequent glycolytic enzymes [16]. Currently, 
FDG-PET is an established method for staging in 
clinical oncology and it is widely used on PET/CT 
scanners that deliver anatomical localization at the 
same time [17]. However, it requires complementary 
approaches to better characterize malignant tissues, 
because FDG uptake is an indirect measure of the 
Warburg effect. Furthermore, it cannot discriminate 
between tumors and tissues that consume high 
amounts of glucose on a regular basis like in the brain, 
heart or during inflammatory processes [13, 18]. 
Magnetic resonance spectroscopic imaging 
(MRSI) has classically been used to study biochemical 
processes non-invasively, although it suffers from a 
low sensitivity and requires long scan times [19]. The 
invention of hyperpolarization (HP) techniques has 
shifted these limits, allowing signal enhancements of 
13C-labelled metabolites by more than five orders of 
magnitude [20]. However, hyperpolarized signals 
decay with the spin-lattice relaxation time (T1) which 
is on the order of a few tens of seconds, limiting the 
time available for signal acquisition and requiring fast 
signal acquisition. Furthermore, supra-physiologic 
concentrations of 13C-metabolites are administered to 
achieve analyzable in vivo spectra in pre-clinical and 
clinical [21] studies. In fact, this could potentially bias 
the quantification of metabolic parameters, but Serrao 
et al. have recently shown that exchange rates are not 
significantly altered by high metabolite concentra-
tions in the blood stream [22].  
Hyperpolarized [1-13C]pyruvate (pyruvate) is 
most often used in vivo, because of its key role in 
glucose metabolism, its fast metabolic conversion to 
lactate, its high achievable polarization level and a 
relatively long T1 [10]. Tumors readily internalize and 
metabolize pyruvate to lactate by lactate 
dehydrogenase (LDH-A). The expression of LDH-A is 
upregulated in many tumors, which results in an 
increased pyruvate-to-lactate conversion [23] that can 
be quantified with MRSI [24].  
So far, only a few sites worldwide attempted to 
assess the flux of glucose through the glycolytic 
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pathway either sequentially or simultaneously with 
FDG-PET and pyruvate imaging (HyperPET [25-28]). 
Witney et al. demonstrated a late treatment effect [29] 
and Menzel et al. [30] showed a qualitative correlation 
between both imaging modalities. Ravoori et al. 
recently detected an early treatment response with 
pyruvate that was not observed with PET/CT [31]. 
However, these studies indicate that sequential 
imaging of FDG uptake and pyruvate-to-lactate 
conversion with different modalities might not be 
ideal, because the metabolic status of an organism 
could change drastically during transport of animals, 
if the delay between the experiments is too long, or if 
anesthesia is interrupted. 
Precise temporal and spatial correlation of 
complementary PET and MR data can inherently be 
achieved with PET/MR. However, it is a relatively 
expensive modality and not a standard technique in 
preclinical and clinical research. Although it has been 
shown that co-registration of sequentially acquired 
PET and MR images is feasible, for instance in brain 
[32], PET/MR is particularly useful for regions of low 
CT contrast. In addition, the ability to perform 
diffusion-weighted imaging could benefit data 
interpretation as variations of the cell density might 
lead to apparently decreased tracer uptake or 
conversion, affecting quantification of PET and MRSI 
data [33]. 
In this study, we established and validated a 
workflow at a clinical whole-body PET/MR for the 
multiparametric characterization of the glycolytic flux 
in a pre-clinical MAT-B-III breast cancer model. We 
analyzed the in vivo correlation of FDG uptake with 
pyruvate-to-lactate conversion and performed a 
longitudinal study with a group of tumor-bearing rats 
to study the effect of changing tumor cellularity on 
metabolic PET and MRSI data.  
Methods 
Chemicals 
All chemicals were used as purchased without 
further purification. Cell culture media (RPMI-1640 
and Mc Coy’s) were obtained from ThermoFisher 
Scientific (Waltham, MA, USA) and medium supplies 
(fetal calf serum, penicillin/streptomycin mixture) 
from Biochrom/Merck (Berlin, Germany). 
[1-13C]pyruvate, OX063 ((tris(8-carboxy-2,2,6,6-tetra- 
(hydroxyethyl)-benzo-[1,2-4,5]-bis-(1,3)-dithiole-4-yl)-
methyl sodium salt) and gadolinium chelate 
(Dotarem) for hyperpolarization were respectively 
obtained from Cambridge Isotope Laboratories 
(Tewksbury, MA, USA), Oxford Instruments 
(Abingdon, United Kingdom) and Guerbet 
Laboratories Ltd. (Villepinte, France). Isoflurane was 
purchased from CP-Pharma (Burgdorf, Germany). 
Pentobarbital (Narcoren) was purchased from Merial 
(Lyon, France). Chemicals for the dynamic nuclear 
polarization (DNP) dissolution buffer were obtained 
from Sigma Aldrich (St. Louis, MO, USA). FDG was 
synthesized on site using a standard technique 
modified from the synthesis reported by Hamacher et 
al. [34] and with chemicals purchased from Sigma 
Aldrich (St. Louis, MO, USA).  
Tumor model 
Animal experiments were approved by the local 
governmental committee for animal protection and 
welfare (Tierschutzbehörde, Regierung von 
Oberbayern).  
Subcutaneous tumors were induced at the right 
flank of eleven female Fischer344 rats (age = six 
weeks, average weight = 146 ± 10 g; Charles River, 
Wilmington, MA, USA) by implantation of 1×106 
MAT-B-III 13762 breast cancer cells derived from 
mammary adenocarcinoma (ATCC, Manassas, VI, 
USA). For this purpose, cells were cultivated in 
RPMI-1640 medium supplied with 10% fetal calf 
serum, 1% penicillin and 1% streptomycin and 
re-suspended in 200 µL Mc Coy’s 5A medium for 
implantation. A tumor growth curve can be found in 
Figure S1. 
Study population 
For quantitative validation of FDG uptake 
measured in a clinical PET/MR scanner, three animals 
were imaged eight days after tumor implantation in a 
small-animal PET/CT scanner (Inveon, Siemens 
Healthcare, Erlangen, Germany) after two hours of 
fasting. Approximately ten hours later, the same 
animals were imaged again after two hours of fasting 
in a clinical 3T PET/MR scanner (Biograph mMR, 
Siemens Healthcare, Erlangen, Germany). 
Furthermore, eight animals were measured in the 
clinical PET/MR scanner eight, ten and thirteen days 
after tumor implantation in a longitudinal study (fed 
ad libitum). One hyperpolarized [1-13C]pyruvate 
measurement was excluded from analysis because of 
respiratory problems during tracer injection, one PET 
scan failed (see workflow) and one animal was 
sacrificed on day ten, because it met a study abortion 
criterion. In total, ten comparable FDG-PET, HP 
[1-13C]pyruvate and DWI measurements for day eight, 
eight for day ten and six for day thirteen were used 
for analysis and clustered into three groups of similar 
ADC values.  
PET/MR workflow  
For PET/MR scans, animals under anesthesia 
(1-3% isoflurane) were placed right lateral and head 
first with the tumor in the middle of the isocenter of 
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the magnet and on top of the center of a flexible 
1H/13C dual-tuned transmit-receive surface coil 
(Rapid Biomedical, Rimpar, Germany). PET scans 
were started with tail-vein injection of FDG.  
During PET acquisition (Figure 1A), a magnetic 
resonance-based attenuation correction ultra-short 
echo time (MRAC UTE), a 3D T1 magnetization- 
prepared rapid acquisition gradient echo (MPRAGE), 
a 3D T2-weighted fluid-attenuated inversion recovery 
(FLAIR), an axial 2D T1-weighted (FLASH) and an 
axial 2D T2-weighted half Fourier acquisition single 
shot turbo spin echo (HASTE) sequence were 
acquired. Metabolic imaging using pyruvate was 
performed at the end of the PET scan (~70-90 min 
after PET start) using an axial 2D chemical shift 
imaging sequence (CSI). For diffusion-weighted 
imaging, a 2D axial spin-echo, echo-planar imaging 
(EPI) sequence was applied. DWI was started after the 
PET scan was finished, because the sequence 
attempted to move the slice position in the isocenter 
of the bed, which interfered with PET acquisition. All 
2D sequences were positioned in the same axial center 
of the tumors. Acquisition parameters of the proton 
MRI sequences are summarized in the supplement 
(Table S1). During PET/MR acquisition, blood 
oxygenation (Expression MR Patient Monitor, Invivo, 
Gainesville, FL, USA) and breathing rate (ECG 
Trigger Unit, Rapid Biomedical, Rimpar, Germany) 
were continuously monitored. With exception of one 
animal that stopped breathing (for about 60 s and then 
resumed breathing) after injection of pyruvate, 
breathing (50 ± 13 min-1) and blood oxygen saturation 
(93 ± 6%) did not show any abnormalities during all 
performed experiments. Blood glucose (cGlc) and 
blood lactate (clac) were determined before each 
measurement (Accutrend Plus, Roche, Basel, 
Switzerland). The average time of animals under 
anesthesia was 155 ± 27 min.  
Tumor region-of-interest (ROI) definition  
Quantification of metabolic and cellular 
parameters was performed for whole tumor ROIs. 
Detailed information will be given in the respective 
image analysis sections. The threshold for the region 
grower for PET analysis was chosen to cover the 
whole tumor in three dimensions including areas of 
lower FDG uptake. The acquisition slices of 
13C-images were oriented in the axial direction with 
the slices being in the middle of the tumors and 
having a slice thickness of 13 mm to cover the tumor 
in the axial direction. ROIs for 13C-analysis were 
defined for the whole tumor in T2-weighted images 
overlaid on 13C-images. For diffusion-weighted 
imaging, three images (per b-value) with a slice 
thickness of 3 mm and a distance of 2 mm (total 
volume: 13 mm) between the slices were acquired to 
cover the same tumor volume as was measured with 
13C-CSI. For histology, four slices per tumor were 
analyzed with a total distance of 7-10 mm between the 
two slice pairs.  
PET/CT acquisition and reconstruction 
FDG-PET scans in the small-animal PET/CT 
were started with a tail-vein injection of FDG (11.5 ± 
0.6 MBq). Three-dimensional PET data were acquired 
in list mode for 60 min followed by a CT-acquisition 
(low dose, 120 projections, 200 ms exposure time, 80 
kVp (peak kilovoltage) x-ray voltage, 500 µA anode 
current at 220° rotation). Images were reconstructed 
in 12×10 s, 6×30 s, and 11×300 s frames using an 
ordered-subsets expectation-maximization 3D 
algorithm with 2 iterations and 16 subsets, followed 
by 18 maximum-a-posteriori iterations (recom-
mended parameters from manufacturer), without 
 
 
Figure 1. Multimodal imaging workflow (A) and addressed metabolic pathways (B). Dynamic 90 min PET acquisition was started with tail-vein injection of [18F]FDG. 
Simultaneously, magnetic resonance-based attenuation correction ultra-short echo time (MRAC UTE), 3D and 2D T1- and T2-weighted proton MRI for determination of tumor 
localization and slice positioning of 13C and DWI acquisition were performed. Dynamic 13C-MRSI was measured after injection of HP pyruvate at the end of the PET scan (70-90 
min after FDG injection). DWI was performed after PET acquisition. Metabolic parameters (glucose uptake and LDH activity) and structural parameters (tumor cellularity) that 
were addressed with PET, MRSI and DWI are given in bold. Acquisition times are indicated with black solid lines. Acquisition parameters for proton MRI can be found in the 
supplement (Table S1). Metabolic pathways (B) that were addressed with FDG-PET and 13C-MRSI are colored in red and blue, respectively. Note that arrows with bigger fonts 
indicate an increased metabolic flux as observable for various tumors. 
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attenuation or scatter correction. The final image 
matrix was 128×128 pixels, 159 axial slices and a pixel 
size of 0.77×0.77×0.80 mm3. The CT images were 
reconstructed with a modified Feldkamp algorithm 
yielding image matrices of 256×256 pixels, 384 axial 
slices and a pixel size of 0.17×0.17×0.17 mm3.  
PET/MR acquisition and reconstruction 
3D FDG-PET data were acquired in list mode for 
90 min after tail-vein injection of FDG (10.5 ± 2.1 
MBq). Images were reconstructed with the same 
framing as described for PET/CT, using a fully 
iterative 3D OSEM (ordered subset expectation 
maximization) algorithm (3 iterations and 21 subsets 
as recommended by the manufacturer) with an 
ultra-short echo time magnetic resonance 
imaging-based attenuation correction (MRAC UTE). 
The final PET image matrix contained 344×344 pixels, 
127 axial slices, and a voxel size of 1.04×1.04×2.03 
mm3 resulting in a FOV of 359×359×258 mm3. 
PET image analysis 
PET analysis was performed in Matlab (The 
MathWorks, Natick, MA, USA). Tumor ROIs were 
semi-automatically segmented using a region grower 
algorithm with the initial seed manually selected. We 
calculated the standard uptake value (SUV) in the 
tumor ROI by normalizing the mean activity 
concentration in the ROI by the injected dose and the 
animal weight. All voxels, in which we measured an 
FDG activity greater than half of the maximum SUV 
(SUVmax) were appended to the ROI by the region 
grower (SUVmean, with SUV > 0.5×SUVmax). The 
threshold was chosen in order to cover the whole 
tumor including areas of lower FDG uptake. All SUV 
values were measured on a 5 min frame 47 min post 
injection.  
In addition, we calculated the total volume of 
voxels with SUVmean > 0.5×SUVmax which is defined as 
the tumor metabolic volume (TMW). The product of 
the SUVmean and the TMW is the total lesion glycolysis 
(TLG). Both TMW and TLG are a measure of the 
metabolic burden [35, 36]. 
For PET Patlak [37] analysis, image-derived 
input functions (IDIFs) were segmented 
semi-automatically with a threshold of 0.7×SUVmax in 
the inferior vena cava in coronal images obtained 
from PET/CT and PET/MR. The average ROI size 
was 21 ± 10 mm3. Tumor time-activity curves were 
fitted to a Patlak kinetic model (fit intervals: 10 min to 
40 min) yielding the composite rate constant Ki 
(K1×k3/(k2+k3)), with k1 being the primary tracer 
uptake rate from blood to free tracer in tissue, k2 the 
tissue clearance rate and k3 the rate of exchange 
between free and trapped tracer in tissue. The rate of 
tumor glucose uptake (MRGlu) was calculated as 
Ki×(cGlc/LC), with LC being the lumped constant 
equaling 0.60 [30]. For PET/MR longitudinal data, Ki 
and MRGlu values were divided by a correction factor 
f = 2.7 that was obtained from the comparison of 
PET/CT and PET/MR data. More detailed 
information for Patlak analysis can be found in the 
supplement (Section S2 and S3).  
Hyperpolarization of pyruvate 
For the HP process, 14 M [1-13C]pyruvate (36.7 ± 
1.9 mg) supplemented with 15 mM OX063 trityl 
radical and 1 mM Dotarem were polarized with a 
HyperSense (Oxford Instruments, Abingdon, United 
Kingdom) for ~30 min at 1.2 K using a microwave 
frequency of 94.155 GHz and 100 mW power. The 
sample was dissolved in a solution pressurized to 10 
bar and heated to 180 °C containing 4.5 ± 0.3 mL 100 
mM phosphate buffered saline (PBS) supplemented 
with 100 mM sodium hydroxide (NaOH) and 0.1 g/L 
sodium ethylenediaminetetraacetic acid (EDTA). 
Finally, the solution for injection contained an average 
pyruvate concentration of 90.3 ± 3.9 mM at pH 7.6 ± 
0.2. The polarization level was about 38% (measured 
at B0 = 1 T, Spinsolve Carbon, Magritek, Aachen, 
Germany) [38]. The hyperpolarized solution was 
rapidly transferred to the clinical PET/MR scanner 
and injected 21.7 ± 2.1 s after dissolution.  
13C-MRSI 
The excitation profile of the 1H/13C surface coil 
was measured as shown in Figure S4. Prior to the in 
vivo experiments, the 13C-resonance frequency was 
determined and a calibration of the B1-field was 
performed using a 5 mL model solution containing 2.2 
M [1-13C]lactate (lactate), 5 mM Dotarem and 0.1% 
sodium azide. The 13C-transmit frequency was set to 
the center between lactate and pyruvate. CSI was 
started at the same time as the injection of 1.0 ± 0.1 mL 
of hyperpolarized pyruvate and injection took 18.0 ± 
5.1 s.  
A slice-selective, 2D phase-encoded CSI 
sequence was applied with the following parameters: 
3 kHz spectral bandwidth; 512 acquisition points; 5.9 
Hz spectral resolution; 8×8 matrix size; 13 mm slice 
thickness; 8 cm FOV; 15° flip angle; 200 ms repetition 
time; 29 excitations; 5.8 s scan time per slice; 20 
consecutive measurements/scan; 118 s total 
acquisition time, 10×10×13 mm3 nominal voxel size. 
The k-space was sampled in elliptic order from the 
center on outwards.  
For qualitative comparison of PET and 
13C-images, a CSI image with a separate animal that 
was not used for quantitative analysis was measured 
using a matrix size of 16×16 and nominal resolution of 
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0.5×0.5×13 mm3. Number of excitations and scan time 
were 128 and 28 s respectively. All other acquisition 
parameters were not changed. 
13C-Image analysis 
Images were reconstructed as described 
previously (Matlab, The MathWorks, Natick, MA, 
USA) [39]. The data were zero-filled by a factor of four 
in both k-space space dimensions and by a factor of 
two in the temporal dimension prior to Fourier 
transformation. In the spectrum of each voxel and for 
each time step, the resonances of lactate and pyruvate 
were quantified by integration.  
The mean of the integrals of the pyruvate and the 
lactate signals were determined for whole tumor 
ROIs. The ROIs were defined from axial T2-weighted 
images overlaid on the 13C-images. Mean signals were 
then fitted with a two-site-exchange model as follows 
[10]: 
𝑑𝑑𝑀𝑀𝑙𝑙𝑙𝑙𝑙𝑙(𝑡𝑡)
𝑑𝑑𝑡𝑡
=+𝑘𝑘𝑝𝑝𝑝𝑝 ∙ 𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡) − 𝑘𝑘𝑝𝑝𝑝𝑝 ∙ 𝑀𝑀𝑝𝑝𝑙𝑙𝑙𝑙(𝑡𝑡) − 𝜌𝜌𝑝𝑝𝑙𝑙𝑙𝑙(𝑀𝑀𝑝𝑝𝑙𝑙𝑙𝑙(𝑡𝑡) −lim𝑡𝑡→∞𝑀𝑀𝑝𝑝𝑙𝑙𝑙𝑙(𝑡𝑡)) (1) 
𝑑𝑑𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡)
𝑑𝑑𝑡𝑡
=
−𝑘𝑘𝑝𝑝𝑝𝑝 ∙ 𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡) + 𝑘𝑘𝑝𝑝𝑝𝑝 ∙ 𝑀𝑀𝑝𝑝𝑙𝑙𝑙𝑙(𝑡𝑡) − 𝜌𝜌𝑝𝑝𝑝𝑝𝑝𝑝(𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡) −lim𝑡𝑡→∞𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡)) (2) 
Mlac and Mpyr are the lactate and pyruvate 
z-magnetizations, kpl and klp are the apparent rate 
constants for the pyruvate-to-lactate exchange and the 
reverse reaction. ρpyr and ρlac are the effective decay 
rates of the pyruvate and the lactate signal including 
T1 relaxation and radiofrequency (RF) excitation. If 
the thermal signals at lim𝑡𝑡→∞(𝑡𝑡)  are neglected, the 
contributions from backward conversions, RF 
excitation and T1-relaxation can be merged into 
effective relaxation rates T1pyr,eff. and T1lac,eff.. Pyruvate 
data were fitted piecewise according to Equation 3:  
 
𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡) = � 𝑝𝑝𝑖𝑖𝑖𝑖𝑖𝑖.𝑇𝑇1𝑝𝑝𝑝𝑝𝑝𝑝,𝑒𝑒𝑒𝑒𝑒𝑒 (1 − 𝑒𝑒−𝑇𝑇1𝑝𝑝𝑝𝑝𝑝𝑝,𝑒𝑒𝑒𝑒𝑒𝑒∙(𝑡𝑡−𝑡𝑡𝑙𝑙𝑝𝑝𝑝𝑝.) 𝑡𝑡𝑙𝑙𝑝𝑝𝑝𝑝 ≤ 𝑡𝑡 ≤ 𝑡𝑡𝑚𝑚𝑙𝑙𝑚𝑚,𝑝𝑝𝑝𝑝𝑝𝑝 − 5.9𝑠𝑠
𝑀𝑀𝑝𝑝𝑝𝑝𝑝𝑝,𝑚𝑚𝑙𝑙𝑚𝑚 𝑒𝑒−𝑇𝑇1𝑝𝑝𝑝𝑝𝑝𝑝,𝑒𝑒𝑒𝑒𝑒𝑒∙(𝑡𝑡−(𝑡𝑡𝑚𝑚𝑙𝑙𝑚𝑚,𝑝𝑝𝑝𝑝𝑝𝑝+5.9𝑠𝑠)) 𝑡𝑡 ≥  𝑡𝑡𝑚𝑚𝑙𝑙𝑚𝑚,𝑝𝑝𝑝𝑝𝑝𝑝 + 5.9𝑠𝑠  (3) 
 
 
where rinj. is the rate of injection, tarr. is the time of 
substrate arrival and tmax,pyr is the time at the observed 
maximum of pyruvate.  
We found that fitting of the lactate signal with 
the following differential equation was more reliable 
than using the input function parameters obtained by 
the pyruvate fit. This was mainly due to the fact that 
the sampling rate of 13C-data was not high enough to 
accurately determine the actual tmax,pyr. For discrete 
values, the simplified differential Equation 4 can be 
expressed as matrix equation for kpl and T1lac,eff. 
dMlac/dt = kpl ∙ Mpyr(t)-T1lac,eff ∙ Mlac(t) (4) 
and solved using the Moore-Penrose 
pseudoinverse. 
Furthermore we calculated the kinetic value 
from the area under the curves (AUC ratios) according 
to the model-free approach of Hill et al. [40] in 
Equation 5:  
𝐴𝐴𝐴𝐴𝐴𝐴 𝑟𝑟𝑟𝑟𝑡𝑡𝑟𝑟𝑟𝑟𝑠𝑠 = ∑ 𝐼𝐼(𝑝𝑝𝑙𝑙𝑙𝑙𝑡𝑡𝑙𝑙𝑡𝑡𝑎𝑎𝑡𝑡𝑡𝑡𝑚𝑚𝑡𝑡𝑝𝑝)������������������������20𝑖𝑖=1
∑ 𝐼𝐼(𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑙𝑙𝑡𝑡𝑎𝑎𝑡𝑡𝑡𝑡𝑚𝑚𝑡𝑡𝑝𝑝)���������������������������20𝑖𝑖=1   (5) 
with I(lactate)tumor and I(pyruvate)tumor being the 
summed mean lactate and pyruvate nuclear magnetic 
resonance (NMR) integrals observed in the same 
tumor ROIs as mentioned above.  
Additionally to analysis of tumor ROIs, we 
analyzed mean pyruvate and lactate integrals 
measured in the whole axial CSI slice, which is similar 
to a slice-selective excitation approach yielding kpl,slice 
and AUC ratiosslice. This avoids errors of manual ROI 
determination but instead includes pyruvate and 
lactate signals from regions outside of the tumor.  
Diffusion-weighted image analysis 
We performed experiments with an ice-water 
phantom [41] to show reproducibility and validation 
for ADC quantification. Detailed information is given 
in the Supplement S5. In vitro and in vivo tumor 
apparent diffusion coefficients (ADC) were calculated 
from the image intensities (S) according to the 
Stejskal-Tanner Equation 6 [42]:  
S = S0∙e(-b∙ADC) (6)  
with S0 being the image signal intensity without 
diffusion-weighting and b being the 
diffusion-weighting factor.  
Calculations were performed using least squares 
fitting and calculations resulted in pixelwise 
ADC-maps (MATLAB, MathWorks, Natik, MA, USA). 
The ADC values were obtained at first by averaging 
the signal intensities in the manually segmented ROI 
and subsequently calculating the ADC value. The 
workflow was performed for three slices per animal to 
cover the whole tumor in the axial direction. Finally, a 
weighted mean of three slice-specific ADC values per 
animal was determined [43, 44]. A representative 
series of T2-weighted images, diffusion-weighted 
images and ADC fits are shown in the supplement 
(Figure S5).  
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Histology  
Seven animals from terminal experiments were 
sacrificed with an excess of pentobarbital (n = 1 and n 
= 6, respectively, ten and thirteen days after tumor 
implantation). One animal was left out for analysis, 
because the PET scan failed as described in the 
workflow section. Tumors and adjacent tissue were 
removed, marked according to their spatial 
orientation and divided in two halves that were 
subsequently fixed in 10% neutral-buffered formalin 
solution for 48 h, dehydrated under standard 
conditions (Leica ASP300S, Wetzlar, Germany) and 
embedded in paraffin. Each half was flattened and 
from each half two 2 um-thin sections, separated by 
200 µm and with a distance of 7-10 mm to the slices 
from the other tumor half (distance of the outer slices) 
were prepared with a rotary microtome (HM355S, 
ThermoFisher Scientific, Waltham, MA, USA), 
collected and subjected to histological analysis. 
Hematoxylin-Eosin (H.-E.) staining was performed on 
deparaffinized sections with Eosin and Mayer’s 
Haemalaun according to a standard protocol. 
The percentage as well as the pattern of necrosis 
(i.e., large central necrosis vs. multifocal small areas of 
necrosis) covering the tumor area were evaluated by 
two experienced pathologists. Representative H.-E. 
stained images are given in the supplement (Figure 
S6). Percentages of necrosis are given as mean (± 
standard deviation) values calculated for all slices 
(Figure S7).  
Measurement of distance between tumor and 
blood vessel 
The distance between the vena cava and the 
center of mass of the tumors (dt-v) was defined in 
T2-weighted images (RadiAnt Dicom Viewer, 
Medixant, Poznan, Poland). 
Statistical analysis 
All data are represented as mean values and 
standard deviations (std). Correlations for all 
quantitative parameters were calculated with a 
two-sided t-test yielding the Pearson 
product-moment coefficient (R) using GraphPad 
Prism (GraphPad Software, Inc., La Jolla, CA, USA). 
Longitudinal data were analyzed with an unpaired 
two-sided t-test. Values of < 0.3, 0.3-0.5 and 0.5-1.0 
were considered as weak, moderate and strong 
correlations, respectively, according to the guidelines 
of Cohen [45] and as reported earlier [46]. The 
statistical significance levels are indicated by 
asterisks, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001. 
Results 
Validation of FDG uptake measured at a 
human PET/MR compared to a small-animal 
PET/CT  
Tumor-time activity curves measured with 
pre-clinical PET/CT and clinical PET/MR are 
displayed in Figure 2A-B. The SUVmax values were 7.4 
± 1.2 and 7.5 ± 0.7 and the SUVmean values were 4.9 ± 
0.5 and 4.8 ± 0.6 for the PET/CT and PET/MR 
respectively, showing no significant difference (t = 47 
min, Figure 2C). For kinetic analysis of FDG uptake, 
image-derived input functions (IDIFs) could 
reproducibly be measured in the inferior vena cava 
(see supplement, Figure S2 [47]) rather than in the 
aorta where the IDIF was not quantifiable [48]. 
However, the area under the curve values of IDIFs 
(Figure S3) were smaller for IDIF measurements at 
the PET/MR (Figure 2E) compared to the PET/CT 
(Figure 2D). This caused an overestimation of 
PET/MR Ki values by a factor of f = 2.7 (Figure 2F).  
Metabolic mapping of hyperpolarized pyruvate 
HP pyruvate was readily observed in the vena 
cava in the first CSI images (t = 5.9 s) after tail-vein 
injection. Lactate was observed in the subsequent data 
sets. The maximum signals of pyruvate and lactate in 
the tumor were observed at 22 ± 4 s and 27 ± 4 s, 
respectively, after the start of the acquisition. 
Representative metabolic images of pyruvate and 
lactate at time t = 23.6 s from a dynamic time course 
are displayed in Figure 3A and Figure 3D, 
respectively. The signal of pyruvate was about 
five-fold higher in the vena cava than in the tumor 
and about ten-fold higher than the maximum lactate 
signal. Effective relaxation rates of pyruvate and 
lactate in tumor ROIs were T1pyr,eff. = 14.6 ± 2.0 s and 
T1lac,eff. = 9.8 ± 2.5 s (n = 24). Hyperpolarized lactate was 
mainly visible in tissues around the vena cava and the 
tumor. AUC ratios and kpl indicated a higher LDH 
activity in the tumors (AUC ratios = 0.28 ± 0.06, kpl = 
0.029 ± 0.009 s-1) than in tissues surrounding the vena 
cava (AUC ratios = 0.10 ± 0.01, kpl = 0.015 ± 0.004 s-1). 
The time course of pyruvate and lactate signals of a 
representative tumor and a non-tumor voxel are 
shown in Figure 3B and Figure 3E. Respective plots of 
the integrals of the dynamic NMR series are given in 
Figure 3C and Figure 3F. Tumor AUC ratios and kpl 
values showed a strong positive correlation (R = 0.62, 
p = 0.0012), as reported in the literature [40]. 
We observed that partial volumes and point 
spread function [49] artifacts caused by both a high 
pyruvate blood signal and a low spatial resolution of 
13C-images influenced the tumor kpl and AUC, 
especially in cases where the tumor was close to the 
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vessel. A positive correlation between the tumor kpl 
and AUC ratios with the distance of the tumor (dt-v) to 
the blood vessel illustrates this effect (R = 0.66, p = 
0.0004 and R = 0.60, p = 0.0020, respectively, Figure 
4A-B).  
 
 
Figure 2. Comparison of the FDG uptake and Patlak analysis of subcutaneous MAT-B-III tumors measured with a pre-clinical PET/CT and a clinical 
PET/MR scanner. FDG uptake curves of subcutaneous tumors obtained from the (A) PET/CT (blue) and the (B) PET/MR (red). (C) The comparison of SUVmax and SUVmean 
does not show a significant difference between the two systems. (D-E) are image-derived input functions (IDIFs) used for Patlak analysis measured in the inferior vena cava for 
PET/CT and the PET/MR images, respectively. (F) shows that the Ki values obtained from PET/MR measurements are overestimated by a factor of 2.7 compared to values 
obtained with the PET/CT. Note that equal thresholds for the region grower algorithm were used to obtain quantitative PET/CT and PET/MR data (tumor: 0.5×SUVmax, input 
function: 0.7×SUVmax). 
 
Figure 3. Dynamic metabolic mapping of the LDH activity of subcutaneous MAT-B-III tumors using hyperpolarized pyruvate. (A) Static image of 
hyperpolarized pyruvate at pyruvate maximum in tissues surrounding the vena cava overlaid on an axial T1-weighted image. A non-tumor voxel is indicated with the green box, 
the tumor is delineated with the green dashed line. (B) Stacked plot of the first ten dynamic 13C-spectra of a non-tumor voxel from (A). (C) Dynamic series of pyruvate and 
lactate NMR signal integrals from (B) and normalized to the maximum integral of pyruvate (Inorm.). Curve fits are given with dashed lines. (D) Static image of hyperpolarized lactate 
at lactate maximum overlaid on an axial T1-weighted image. (E) Stacked plot of the first ten NMR spectra from a representative tumor voxel (green box in (D)). (F) Dynamic 
series of pyruvate and lactate NMR signal integrals of the tumor ROI and normalized to the maximum integral of pyruvate. Curve fits are given with dashed lines. Note that the 
pyruvate signal was about a factor of ten higher than that of lactate. 
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Figure 4. Correlation between kpl (A) and AUC ratios (B) with distance between the major blood vessel and the center of MAT-B-III tumors (dt-v). Best fit 
(solid line) and 95% confidence bands (dashed lines). 
  
Figure 5. Qualitative comparison of simultaneously imaged FDG uptake and pyruvate-to-lactate exchange in MAT-B-III tumor-bearing rats. (A) Coronal 
slice of a late frame PET image overlaid on the respective slices of an MPRAGE image. Static axial images of pyruvate (B), lactate (C) and FDG (D) in the same orientation. (E) 
is the ratio of (C) and (B) showing a higher lactate to pyruvate ratio in the tumor than observed in the surrounding tissue, which correlates well with the high FDG uptake shown 
in (D). Note that for CSI images, only pixels with a signal > 20% of the maximum signal of hyperpolarized pyruvate and lactate are displayed, respectively. Note further that the 
pyruvate signal is about a factor of ten higher than the lactate signal and that the nominal resolution of 13C-images was two-fold higher than the resolution used for quantitative 
analysis. 
 
Qualitative comparison of PET and HP-MRSI 
Our PET/MR setup enabled the acquisition of 
three-dimensional T1- and T2-weighted proton images 
of whole animals (except the head) with a resolution 
below one cubic millimeter (Table S1). This allowed 
an accurate tumor delineation in the axial direction, 
which facilitated the positioning of 2D proton images 
that were used for anatomical referencing of MRSI 
and DWI. Quantification of pyruvate-to-lactate 
exchange was based on tumor ROI definition on 
13C-images overlaid with 2D T2-weighted proton 
images. Two- and three-dimensional T1-weighted 
proton images were used for visualization of 
inherently co-registered PET or MRSI data as shown 
in Figure 5.  
A coronal (from 3D T1-weighted images) and an 
axial static late frame FDG image (t = 55 min) show 
high FDG uptake in tumors (Figure 5A and Figure 
5D). Representative static metabolic images of 
hyperpolarized pyruvate and lactate are displayed in 
Figure 5B and Figure 5C revealing pyruvate uptake 
and conversion to lactate in the same region as given 
in Figure 5D. Figure 5E displays the ratio of 
lactate-to-pyruvate and indicates a high 
pyruvate-to-lactate exchange in the tumor region, 
which qualitatively correlates well with a high FDG 
uptake (Figure 5D).  
Quantitative comparison of PET and DWI and 
HP MRSI data 
We measured 24 multimodal longitudinal 
PET/MR data sets to investigate the correlation 
between FDG uptake and pyruvate-to-lactate 
exchange and the effect of tumor cellularity on 
metabolic data. However, it has to be noted again that 
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ROIs for PET, DWI and MRSI analysis did not exactly 
correlate in space, as mentioned in the methods.  
ADC values significantly increased with tumor 
growth (Figure S8A) due to increasing necrosis. This 
was verified by histological analysis (Figure S7) that 
showed a positive but not significant correlation 
between ADC and percentage of necrosis for the 
terminal samples (R = 0.46, p = 0.2150, n = 7). 
Metabolic data showed a negative correlation with 
increasing necrosis without significance (SUVmean: R = 
-0.46, p = 0.2960, Ki: R = -0.68, p = 0.0916), whereas 
only a very weak trend was observable for 13C-data 
(kpl: R = -0.23, p = 0.6147). Comprehensive plots are 
shown in Figure S7. Note, that only small amounts of 
granulation tissue in the necrotic parts and immune 
cell infiltration were observed.  
Based on these observations, we clustered 
quantitative 13C- and PET data into three groups of 
low, medium and high ADC values: (0.57 ± 0.04)×10-3 
mm2s-1, (0.85 ± 0.09)×10-3 mm2s-1 and (1.22 ± 0.10)×10-3 
mm2s-1 (with n = 13, n = 7 and n = 4, respectively). We 
then analyzed the correlation of quantitative PET and 
13C-data of the low ADC group in order to exclude 
partial volume effects that affect metabolic data 
caused by a varying tumor cellularity (Figure 6). 
Tumor kpl exhibited a significant positive 
correlation with SUVmean (R = 0.59, p = 0.0352, Figure 
6A) and Ki (R = 0.57, p = 0.0399, Figure 6C). A similar 
but not significant trend was observed with SUVmax (R 
= 0.51, p = 0.0761, Figure 6B) and no correlation was 
seen with MRGlu (R = 0.05, p = 0.8636, Figure 6D). 
Tumor AUC ratios significantly correlated with 
SUVmean (R = 0.59, p = 0.0326, Figure 6E), SUVmax (R = 
0.55, p = 0.0498, Figure 6F) and Ki (R = 0.68, p = 0.0103, 
Figure 6G), but not with MRGlu (R = 0.36, p = 0.2245, 
Figure 6H). Slice-selective kpl and AUC ratios, 
excluding errors from manual tumor ROI definition, 
also showed a positive correlation with quantitative 
PET data: kpl, slice with SUVmean: R = 0.56, p = 0.0481 and 
with Ki: R = 0.65, p = 0.0158; AUC ratiosslice with Ki: R = 
0.70, p = 0.0079 and with MRGlu: R = 0.81, p = 0.0008. 
A comprehensive correlation matrix for tumors with a 
similar ADC can be found in the supplement (Table 
S2).  
Longitudinal PET data showed a significant 
inverse correlation with ADC, while a similar but not 
significant trend was observed for kpl. No correlation 
or trend was observed between AUC ratios and ADC. 
Representative correlation plots of SUVmean and kpl 
with ADC are given in Figure 7. A comprehensive 
matrix of Pearson correlation coefficients for 
longitudinal data can be found in Table 1, excluding 
slice-selective-like 13C-data analysis (see Table S3). 
Overall, kpl (Figure S8C) and PET uptake 
(SUVmean, SUVmax, Ki and MRGlu) apparently 
decreased (Figure S8D-G) for bigger tumors. With 
tumor growth, the tumor metabolic volumes (TMW, 
Figure S8H) and the total lesion glycolysis (TLG, 
Figure S8I) increased and showed a strong correlation 
with ADC values (R = 0.81, p < 0.0001; R = 0.73, p < 
0.0001, respectively, Table 1) and with the blood 
lactate concentration (R = 0.60, p = 0.0020; R = 0.51, p = 
0.0118, respectively; Table 1 and Figure S8J). In 
addition, we detected an inverse correlation of PET 
SUVmean /SUVmax and kpl with blood lactate 
concentration (R = -0.52, p = 0.0099; R = -0.48, p = 
0.0172; R = -0.44, p = 0.0314; Table 1), which increases 
for animals with bigger tumors. Blood glucose levels 
slightly decreased but without significance (Figure S8 
K). AUC ratios did not change significantly and solely 
correlated with SUVmean (R = 0.41, p = 0.0484). Similar 
but not significant trends were observed for their 
correlations with SUVmax, Ki and MRGlu (R = 0.37, p = 
0.0728; R = 0.37, p = 0.0747; R = 0.25, p = 0.2374). For kpl, 
we observed significant positive correlations with 
tumor SUVmean /SUVmax (R = 0.67, p = 0.0004; R = 0.61, 
p = 0.0014) and Ki (R = 0.65, p = 0.0006), which was not 
detected for MRGlu (R = 0.34, p = 0.1081).  
 
Table 1. Pearson correlation coefficients for [18F]FDG PET, [1-13C]pyruvate CSI, DWI 
 SUVmean SUVmax Ki MRGlu kpl AUC rat dt-v TMW TLG ADC clac cglc 
SUVmean 1            
SUVmax 0.99**** 1           
Ki 0.68*** 0.60** 1          
MRGlu 0.65*** 0.58** 0.94**** 1         
kpl 0.67*** 0.61** 0.65*** 0.34n.s. 1        
AUC rat 0.41* 0.37n.s. 0.37n.s. 0.25n.s. 0.62** 1       
dt-v 0.25n.s. 0.19n.s. 0.45*. -0.07.n.s. 0.66*** 0.60** 1      
TMW -0.49* -0.49* -0.37n.s -0.34n.s. -0.33n.s. 0.21n.s. 0.22n.s. 1     
TLG -0.29n.s. -0.29n.s. -0.27n.s. -0.24n.s. -0.21n.s. 0.38n.s. 0.26n.s. 0.95**** 1    
ADC -0.45* -0.46* -0.36n.s -0.37n.s. -0.38n.s. 0.03n.s. 0.38n.s. 0.81**** 0.73**** 1   
clac -0.52** -0.48* -0.30n.s. -0.19n.s. -0.44* -0.13n.s. 0.08n.s. 0.60** 0.51* 0.35n.s. 1  
cglc 0.14n.s 0.13n.s. 0.17n.s. 0.49** -0.17n.s. 0.11n.s. -0.20n.s. 0.02n.s. 0.06n.s. -0.11n.s. 0.17n.s. 1 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
ADC: apparent diffusion coefficient; AUC rat: AUC ratios; cglc,: blood glucose concentration; clac: blood lactate concentration; dt-v: distance of tumor to central blood vessel; Ki: 
composite rate constant; kpl: pyruvate-to-lactate exchange rate; MRGlu: metabolic rate of glucose utilization; n.s.: not significant; SUVmax: maximum standard uptake value; 
SUVmean: mean standard uptake value; TLG: total lesion glycolysis, TMW: tumor metabolic volume. 
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Figure 6. Correlation plots of FDG uptake and hyperpolarized pyruvate CSI data of tumors with similar ADC values. Correlation of kpl with (A) SUVmean, (B) 
SUVmax, (C) Ki and (D) MRGlu. Correlation of AUC ratios with (E) SUVmean, (F) SUVmax, (G) Ki and (H) MRGlu. Best fit (solid line) and 95% confidence bands (dashed lines). The 
mean ADC of analyzed tumors was (0.57 ± 0.04)×10-3 mm2s-1 (n = 13). 
 
Discussion 
We established and validated a multimodal 
imaging workflow on a whole-body PET/MR scanner 
to characterize the Warburg effect in a pre-clinical 
tumor model in rats. Using this workflow, we 
addressed the glycolytic flux in tumors and analyzed 
the effect of tumor growth on longitudinal metabolic 
data. Our setup enables the acquisition of 
high-resolution anatomical images and the 
quantification of physiological and biochemical data 
with PET, MRSI and DWI in one scan session. 
Furthermore, it has potential for translation to large 
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animal models [25, 26, 28] and into the clinic, where it 
could prove the oncological value of hybrid PET/MR. 
 FDG is an important tracer for diagnosis, 
staging and response to treatment monitoring of 
malignant tissues [17]. Comparative measurements 
with the gold-standard for pre-clinical imaging 
(PET/CT) showed that tumor SUVs (tumor size: >500 
mm3) can be measured reliably using a clinical system 
that has an isotropic spatial resolution of 4.3 mm [50]. 
However, quantification of FDG uptake could be 
biased due to false-positive results of glycolytic 
granulation tissue and infiltrating immune cells [51]. 
Histological analyses detected only a low proportion 
of fibroangioblastic granulation tissue consistent with 
a mesenchymal reaction to tumor implantation, 
whereas no distinct differences between animals were 
noticed. Furthermore, only scarce immune cell 
infiltration (mainly consisting of lymphocytes) 
surrounding the tumor tissue was observed and only 
single immune cells were present within the neoplasia 
(Figure S6).  
In small structures like the inferior vena cava (~3 
mm diameter for rats [52]), the activity recovery is 
biased due to partial volume effects, which leads to an 
overestimation of the composite rate constant (Ki). The 
spatial resolution of the PET/CT (<1.5 mm [53]) is 
about a factor of three higher than that of the 
PET/MR, allowing a better quantification of the input 
function and correction of the PET/MR data. 
However, for future studies we seek to approximate 
this correction factor more accurately either by 
measurements with dynamic contrast-enhanced 
(DCE) MRI [54] or by invasive arterial blood sampling 
[55]. Nevertheless, it should be noted that input 
functions could reproducibly be measured (Figure S2) 
in the inferior vena cava [47, 48] with a clinical 
PET/MR, enabling a quantification of tumor glucose 
consumption (MRGlu) even though values are biased.  
Chemical shift imaging (CSI) is a reliable 
sequence to acquire spatially resolved spectroscopic 
data in vivo. However, CSI requires a single excitation 
for the acquisition of each position in the k-space for 
spatial information, and thus results in relatively long 
scan times and an ineffective use of HP 
magnetization. Nevertheless, we were able to perform 
time-resolved CSI measurements with a matrix size of 
10×10×13 mm3 and obtained time courses of 
pyruvate-to-lactate exchange that allowed a 
quantification of in vivo rate constants of LDH. 
However, due to the low image resolution, we 
defined whole tumor ROIs including necrotic areas 
for analysis. This caused partial volume effects likely 
yielding smaller apparent rate constants (kpl and 
AUC). In addition, quantitative LDH measures 
(Figure 4) were further underestimated due to partial 
volumes and point spread function artifacts [49], in 
particular for the pyruvate signal in the vena cava, 
likewise caused by the low image resolution. Methods 
to partially compensate for such artifacts would for 
instance be the inclusion of an arterial [56] or 
image-derived input function for pyruvate. However, 
we found that due to the low data sampling rate, the 
latter approach was not as reliable as solving the 
differential equation (Equation 4) with the 
pseudoinverse of the matrix equation. At this point it 
should also be noted that a lower sensitivity of the 
13C-coil further away from its surface probably also 
impeded optimal quantification (Figure S4). In future, 
implementation of fast state-of-the-art imaging 
sequences like IDEAL spiral CSI [57], spectral-spatial 
EPI [58] or echo planar spectroscopic imaging (EPSI) 
[39] could be used to increase spatial resolution, 
which will improve the quantification of in vivo 
13C-data.  
In the past, several studies sequentially 
measured FDG uptake and pyruvate-to-lactate 
 
Figure 7. Correlation of SUVmean (A) and kpl (B) with ADC. Longitudinal data were clustered into three groups (black, red, blue) of different ADC values to analyze the 
effect of tumor cellularity on metabolic data. Best fit (solid line) and 95% confidence bands (dashed lines). 
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exchange on consecutive days [29]. Menzel et al. 
noticed that longer delays between experiments might 
change the glucose metabolism, obscuring the 
biological significance of metabolic information [30]. 
Simultaneously acquired FDG-PET and HP-pyruvate 
MRSI data for tumors with similar cell density herein 
demonstrated a positive qualitative (Figure 5) and 
quantitative (Figure 6) correlation between FDG 
uptake and LDH activity. However, metabolic images 
from different acquisitions were not precisely 
matched in space and correlations of quantitative data 
are probably still biased. In the future, this could be 
improved by an analysis of ROIs that are identical in 
space and dimension. Furthermore, provided that the 
spatial resolution of MRSI could be improved, 
inclusion of a voxel-wise [25] or histogram-based 
analysis could be beneficial to address tumor 
heterogeneity in greater depth [44]. 
Our workflow included diffusion-weighted 
imaging to address changes of tumor cellularity with 
tumor growth, because variations of tissue density 
and “tissue organization and extracellular space 
tortuosity” [44] can affect image-derived FDG uptake 
and pyruvate-to-lactate conversion. DWI is an 
emerging technique in oncology for diagnosis, 
monitoring and outcome prediction of 
malignancies. However, the diffusion encoding is 
inherently sensitive to motion and the imaging 
readout based on single-shot echo planar imaging 
(EPI) is prone to image distortions, as partially 
observed in our study (Figure S5). This could lead to 
quantification errors. We therefore performed 
comparative measurements with standardized 
phantoms, which revealed a good reproducibility of 
ADC measurements between different systems, 
yielding values in agreement with the literature 
(Supplement S5). 
As ADCs significantly changed with tumor 
growth, we clustered longitudinal data in three 
groups of low, medium and high ADC. By 
minimizing the influence of variations in cell density 
on metabolic data, the correlation of FDG uptake 
(SUVmean and Ki) and pyruvate-to-lactate exchange 
indicates that a major portion of consumed glucose is 
reduced via pyruvate to lactate for the low ADC 
group. Tumors use oxidative glycolysis to generate 
fast energy from glucose and fulfill their anabolic 
needs [13]. The excessive lactate production is crucial 
for invasion and immune evasion of tumors, 
facilitating their survival and metastasis [59]. A 
quantitative measure of the lactate production in 
tumors (kpl or AUC ratios) is therefore valuable 
information that is complementary to FDG-PET and 
will potentially allow a more precise and 
patient-specific phenotyping.  
Our setup enables the simultaneous 
quantification of FDG uptake, LDH activity and 
tumor cellularity to analyze the impact of tumor 
tissue density on metabolic data. In fact, negative 
correlations of longitudinal PET and DWI (Table 1 
and Figure 7) data showed that the measured FDG 
concentration (e.g., SUVmean or Ki vs. ADC) decreases 
with decreasing tumor cellularity (Figure S8). This 
was validated by histology (Figure S7) and is in 
agreement with the literature [33, 60-62]. Similar 
effects were observed with 13C-data (kpl), but we 
assume that a rather imprecise quantification caused 
by a limited spatial resolution of our 13C image 
obscured the significance. In addition, kpl values 
appeared to reflect longitudinal averaging effects 
better than AUC ratios, where no trend was observed 
for the correlation with ADC.  
With tumor growth, the overall tumor cellularity 
decreased while the absolute number of active tumor 
cells increased. This was indicated by increasing 
TMW and a strong positive correlation of the 
respective parameters (ADC and TMW). Thus, the 
absolute amount of FDG uptake (TLG) and lactate 
production in tumors both increased, which led to a 
progressive lactate acidification of animals. This was 
reflected by an increasing blood lactate concentration 
(clac) for animals with bigger tumors and its strong 
positive correlation with TMW and TLG [63]. 
Finally, longitudinal PET and 13C-data also 
showed a positive correlation (kpl with 
SUVmean/SUVmax and Ki, AUC ratios with SUVmean). 
Taking the results of the low ADC group and the 
correlations of the longitudinal data with ADC into 
account, we conclusively assume that this correlation 
is a combined effect of the Warburg effect and partial 
volume effects.  
The simultaneous acquisition of high-resolution 
anatomical images, DWI, PET and hyperpolarized 
MRSI data is now possible with hybrid PET/MR in a 
clinical environment [25, 26, 28]. Better acquisition 
schemes for fMRI and MRSI and the growing number 
of approved PET tracers and hyperpolarized probes 
will further help to characterize tumor biology in 
greater depth.  
Conclusions 
We established and validated a multimodal 
imaging workflow for a clinical PET/MR scanner to 
simultaneously quantify glucose uptake, LDH activity 
and cell density in rodents with PET, hyperpolarized 
MRSI and DWI. Despite resolution limitations of 
dynamic 13C-data, we demonstrated a good 
correspondence between high glucose uptake and 
elevated LDH activity in tumors of similar cellularity. 
This indicates that a major portion of glucose is 
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reduced to lactate in the analyzed tumor model. 
Longitudinal DWI data showed a decrease in cell 
density during tumor growth, which affected the 
quantification of both PET and MRSI data. 
Our workflow includes a multiparametric and 
non-invasive tumor characterization that can possibly 
be applied to larger animal models with potential for 
clinical applications paving the way for tailored and 
patient-specific therapy approaches. 
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